Molecular diagnostics of primary billary cirrhosis

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 6, 2008, Pages 621-634

  Rigopoulou, Eirini I ^a   Dalekos, George N ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Anti PDC E2 antibodies; Antigp210 antibodies; Antimitochondrial antibodies; Antinuclesr antibodies; Antisp 100 antibodies; Autoimmune cholestatic liver diseases; Primary billary diagnosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CELL NUCLEUS ANTIGEN; MITOCHONDRION ANTIBODY;

ALGORITHM; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; AUTOIMMUNITY; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; ISOTOPE LABELING; METHODOLOGY; NONHUMAN; NUCLEAR PORE COMPLEX; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY;

EID: 74849087489     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.6.621     Document Type: Review

References (103)

1. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003;362:53-61
2. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-73
3. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004;363:533-44
4. Selmi C, Invernizzi P, Miozzo M, et al. Primary biliary cirrhosis: does X mark the spot? Autoimmun Rev 2004;3:493-9
5. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003;7:759-77
6. Strassburg CP, Manns MP. Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:585-99
7. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003;98:241-3
8. Strassburg CP, Jaeckel E, Manns MP. Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:595-601
9. Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin liver Dis 2005;25:298-310
10. Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 20076;27:161-72
11. MacKay IR. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med 1958;258:185-8
12. Berg PA, Doniach D, Roitt IM. Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J Exp Med 1967;126:277-90
13. Frazer IH, MacKay IR, Jordan TW, et al. Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. J Immunol 1985;135:1739-45
14. Ishii H, Saifuku K, Namihisa T. Multiplicity of mitochondrial inner membrane antigens from beef heart reacting with antimitochondrial antibodies in sera of patients with primary biliary cirrhosis. Immunol Lett 1985;9:325-30
15. Lindenborn-Fotinos J, Baum H, Berg PA. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985;5:763-9
16. Gershwin ME, MacKay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70kD mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-31
17. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399-402
18. Ishibashi H, Shimoda S, Gershwin ME. The immune response to mitochondrial autoantigens. Semin Liver Dis 2005;25:337-46
19. Moteki S, Leung PS, Dickson ER, et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996;23:436-44
20. Leung PS, Chuang DT, Wynn RM, et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformations epitope. Hepatology 1995;22:505-13
21. Berg PA, Klein R. Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 1995;15:281-92
22. Palmer JM, Yeaman SJ, Bassendine MF, et al. M4 and M9 autoantigens in primary biliary cirrhosis - a negative study. J Hepatol 1993;18:251-4
23. Neuberger J, Bradwell A. Anti-mitochondrial antibodies in primary biliary cirrhosis. J Hepatol 2002;37:712-6
24. Zachou K, Rigopulou EI, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical diagnosis and to study pathogenesis of the disease. J Autoimmune Dis 2004;1:2
25. Dalekos GN, Zachou K, Liaskos C, et al. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002;13:293-303
26. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group. J Hepatol 2004;41:677-83
27. Rigopoulou EI, Davies ET, Bogdanos DP, et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007;27:1226-31
28. Nishio A, Keefe EB, Gershwin ME. Immunopathogenesis of primary biliary cirrhosis. Semin Liver Dis 2002;22:291-302
29. Manns M, Gerken G, Kyriatsoulis A, et al. Two different subtypes of antimitochondrial antibodies are associated with primary biliary cirrhosis: identification and characterization by radioimmunoassay and immunoblotting. Hepatology 1987;5:893-9
30. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34:243-8
31. Kadokawa Y, Omagari K, Hazama H, et al. Evaluation of newly developed ELISA using MESACUP-2 Test Mitochondrial M2 kit for the diagnosis of primary biliary cirrhosis. Clin Biochem 2003;36:203-10
32. Muratori P, Muratori L, Gershwin ME, et al. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 2004;135:154-8
33. Tanaka A, Miyakawa H, Luketic VA, et al. The diagnostic value of anti-mitochondrial antibodies, especially in primary biliary cirrhosis. Cell Mol 2002;48:295-9
34. Gabeta S, Norman GL, Liaskos C, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007;27:378-87
35. Nishio A, Van de Water J, Leung PS, et al. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997;25:1085-9
36. Floreani A, Baragiotta A, Pizzuti D, et al. Mucosal IgA defect in primary biliary cirrhosis. Am J Gastroenterol 2002;97:508-10
37. Gatselis NK, Stefos A, Gioti C, et al. Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. Liver Int 2007;27:280-3
38. Malmborg AC, Shultz DB, Luton F, et al. Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. J Autoimmun 1998; 11:573-80
39. Matsumura S, Van de Water J, Leung P, et al. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004;39:1415-22
40. Gershwin ME, Ansari AA, MacKay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-25
41. Kisand KE, Kisand KV, Karvonen A-L, et al. Antibodies to pyruvate dehydrogenase in primary biliary cirrhosis: correlation with histology. APNIS 1998;106:884-92
42. Nakajama M, Shimizu H, Miyazaki A, et al. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary bilary cirrhosis? J Gastroenterol 1999;34:607-12
43. Tanaka A, Nezu S, Uegaki S, et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann NY Acad Sci 2007;1107:259-70
44. Masuda J, Omagari K, Ohba K, et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-axo-acid dehydrogenase complex in primary biliary cirrhosis. Dig Dis Sci 2003;48:932-8
45. Omagari K, Kadokawa Y, Nakamura M, et al. IgA class antibodies to 2-oxo-acid dehydrogenase complex are not predictive markers of histopathological progression in primary biliary cirrhosis. Autoimmunity 2006;39:107-12
46. Van Norstrand MD, Malinchoc M, Lindor KD, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997;25:6-11
47. Joshi S, Cauch-Dudek K, Heathcote J, et al. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002;97:999-1002
48. Benson GD, Kikuchi K, Miyakawa H, et al. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2004;11:129-33
49. Omagari K, Hazama H, Kohno S. Enzyme inhibition assay for pyruvate dehydrogenase complex: Clinical utility for the diagnosis of primary biliary cirrhosis. World J Gastroenterol 2005;11:6735-9
50. MacKay IR, Whittingham S, Fida S, et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 2000;174:226-37
51. Bogdanos DP, Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006;26:633-5
52. Miyakawa H, Tanaka A, Selmi C, et al. Serum reactivity against bacterial pyruvate dehydrogenase: increasing the specificity of anti-mitochondrial antibodies for the diagnosis of primary biliary cirrhosis. Clin Dev Immunol 2006;13:289-94
53. Rigopoulou EI, Bogdanos D-P, Liaskos C, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007;380:118-21
54. Liaskos C, Norman GL, Papamichalis P, et al. A new ELISA simultaneously detects primary biliary cirrhosis-specific mitochondrial and nuclear autoantibodies [abstract syllabus, p. 270]. Autoimmun Rev 2006
55. Oertelt S, Rieger R, Semi C, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659-65
56. Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-7
57. Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004;2:1116-22
58. Szostecki C, Guldner HH, Will H. Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Semin Liver Dis 1997;17:71-8
59. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528-32
60. Worman HJ, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003;2:211-7
61. Remmel T, Piirsoo A, Koiveer A, et al. Clinical significance of different antinuclear antibodies patterns in the course of primary biliary cirrhosis. Hepatogastroenterology 1996;43:1135-40
62. Marasini B, Gagetta M, Rossi V, et al. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001;60:1046-9
63. Orton SM, Peace-Brewer A, Schmitz JL, et al. Practical evaluation of methods for detection and specificity of autoantibodies to extractable nuclear antigens. Clin Diagn Lab Immunol 2004;11:297-301
64. Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007;26:831-8
65. Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995;10:438-45
66. Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55:388-94
67. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27
68. Bogdanos DP, Liaskos C, Pares A, et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007;45:1583
69. Sternsdorf T, Guldner HH, Szostecki C, et al. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995;42:257-68
70. Invernizzi P, Podda M, Battezzati PM, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001;34:366-72
71. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003;98:241-3
72. Ruffatti A, Arslan P, Floreani A, et al. Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. J Clin Immunol 1985;5:357-61
73. Lozano F, Parés A, Borche L, et al. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology 1988;8:930-8
74. Lassoued K, Guilly MN, Andre C, et al. Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol 1988;74:283-8
75. Lassoued K, Brenard R, Degos F, et al. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology 1990;99:181-6
76. Courvalin JC, Lassoued K, Bartnik E, et al. The 210-kD nuclear envelope polypeptide recognised by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990;86:279-85
77. Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993;178:2237-42
78. Wesierska-Gadek J, Hohenauer H, Hitchman E, et al. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J Exp Med 1995;182:1159-62
79. Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005;42:386-92
80. Luettig B, Boeker KH, Schoessler W, et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 1998;28:824-8
81. Nickowitz RE, Wozniak RW, Schaffner F, et al. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994;106:193-9
82. Itoh S, Ichida T, Yoshida T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998;13:257-65
83. Miyachi K, Hankins RW, Matsushima H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003;20:247-54
84. Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-44
85. Miyachi K, Shibata M, Onozuka Y, et al. Primary biliary cirrhosis sera recognize not only gp210 but also proteins of the p62 complex bearing N-acetylglucosamine residues from rat liver nuclear envelope. Anti-p62 complex antibody in PBC. Mol Biol Rep 1996;23:227-34
86. Wesierska-Gadek J, Hohenuer H, Hitchman E, et al. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840-7
87. Wesierska-Gadek J, Klima A, Komina O, et al. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann NY Acad Sci 2007;1109:519-30
88. Courvalin JC, Lassoued K, Worman HJ, et al. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. Exp Med 1990;172:961-7
89. Szostecki C, Krippner H, Penner E, et al. Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin Exp Immunol 1987;68:108-16
90. Szostecki C, Guldner HH, Netter HJ, et al. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990;145:4338-47
91. Evans J, Reuben A, Craft J. PBC 95k, a 95-kilodalton nuclear autoantigen in primary biliary cirrhosis. Arthritis Rheum 1991;34:731-6
92. Szostecki C, Will H, Netter HJ, et al. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol 1992;36:555-64
93. Züchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997;26:1123-30
94. Muratori P, Muratori L, Cassani F, et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002;127:172-5
95. Rigopoulou EI, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. Scand J Gastroenterol 2004;39:406-7
96. Wichmann I, Montes-Cano MA, Respaldiza N, et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol 2003;38:996-9
97. Bogdanos DP, Vergani D, Muratori P, et al. Specificity of anti-sp100 antibody for primary biliary cirrhosis. Scand J Gastroenterol 2004;39:405-6
98. Janka C, Selmi C, Gershwin ME, et al. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology 2005;41:609-16
99. Tozzoli R. Recent advances in diagnostic technologies and their impact in autoimmune diseases. Autoimmun Rev 2007;6:334-40
100. Robinson WH, Steinman L, Utz PJ. Proteomics technologies for the study of autoimmune disease. Arthritis Rheum 2002;46:885-93
101. Venkatasubbarao S. Microarrays - status and prospects. Trends Biotechnol 2004;22:630-7
102. Fathman CC, Soares L, Chan SM, et al. An array of possibilities for the study of autoimmunity. Nature 2005;435:605-11
103. Oertelt S, Selmi C, Invernizzi P, et al. Genes and goals: an approach to microarray analysis in autoimmunity. Autoimmun Rev 2005;4:414-22